Airna
Cambridge, Massachusetts, United States · Biotechnology, Health Care · 88 employees
Airna, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+.
Funding history
- Series series b — $155.0M — Apr 2025
- Series series a — $60.0M — Jul 2024
Recent signals
- Jun 02, 2026: AIRNA Appoints Todd Bazemore as President and Chief Executive Officer
- Aug 06, 2025: AIRNA Appoints Tamara Joseph as Chief Legal Officer
- Apr 01, 2025: Raised $155.0M in Series series b
- Jan 31, 2025: AIRNA Appoints Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer and Colleen Tucker as Head of People
- Jul 31, 2024: Raised $60.0M in Series series a
See plans & pricing → Track Airna’s funding, hiring, and signals — with verified contacts — on Fundz.